Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Oncotargets and Therapy
|
August 1, 2022
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
Hashim Mann, Raymond L Comenzo
Blood Reviews
|
July 27, 2021
Smoldering multiple myeloma - Past, present, and future
Hashim Mann, Vatsala Katiyar, Cindy Varga, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
May 1, 2023
Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
Lin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
International Journal of Cardiology
|
June 30, 2020
Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
Tauseef Akhtar, Juan Del Cid Fratti, Jishanth Mattumpuram, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 8, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
Journal of Clinical and Translational Science
|
August 30, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
British Journal of Haematology
|
October 8, 2024
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo
Lin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances
|
August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Oncotargets and Therapy
|
August 1, 2022
Evaluating the Therapeutic Potential of Idecabtagene Vicleucel in the Treatment of Multiple Myeloma: Evidence to Date
Hashim Mann, Raymond L Comenzo
Blood Reviews
|
July 27, 2021
Smoldering multiple myeloma - Past, present, and future
Hashim Mann, Vatsala Katiyar, Cindy Varga, et al.
Cellular Oncology (Dordrecht, Netherlands)
|
May 1, 2023
Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells
Lin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
International Journal of Cardiology
|
June 30, 2020
Factors associated with bleeding events in patients on rivaroxaban for non-valvular atrial fibrillation: A real-world experience
Tauseef Akhtar, Juan Del Cid Fratti, Jishanth Mattumpuram, et al.
Medrxiv : the Preprint Server for Health Sciences
|
June 8, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNF-α antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
Journal of Clinical and Translational Science
|
August 30, 2021
Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFα-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure
Hilal Hachem, Amandeep Godara, Courtney Schroeder, et al.
British Journal of Haematology
|
October 8, 2024
Combined MEK1/2 and ATR inhibition promotes myeloma cell death through a STAT3-dependent mechanism in vitro and in vivo
Lin Li, Xiaoyan Hu, Jewel Nkwocha, et al.
Blood
|
October 4, 2024
Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma
Surbhi Sidana, Krina K Patel, Lauren C Peres, et al.
Blood Advances
|
August 28, 2025
Safety and Efficacy of BCMA directed Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Plasma Cell Leukemia
Gliceida M Galarza Fortuna, Lauren C Peres, Elena Nazarenko, et al.
Page
of 1